Diabetic kidney disease: Act now or pay later

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 331-333

  Atkins, R C ^a   Zimmet, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DIABETIC NEPHROPATHY; HEALTH PROMOTION; HUMAN; INTERNATIONAL COOPERATION; PRIORITY JOURNAL; SHORT SURVEY;

DIABETIC NEPHROPATHIES; HUMANS;

EID: 75649140890     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp757     Document Type: Short Survey

References (28)

1. International Diabetes Federation and International Society of Nephrology. Diabetes and kidney disease: time to act. 2003, International Diabetes Federation and International Society of Nephrology, Brussels
2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
4. Yoon K et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688
5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: D Gan (ed). Diabetes Atlas 3rd edn. Brussels: International Diabetes Federation, 2006, pp. 15-109
6. Reutens AT, Prentice L, Atkins R. The Epidemiology of Diabetic Kidney Disease. In J Ekoé et al. (ed). The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: Wiley, 2008, pp. 499-518
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.: Bethesda. pp. 239-254
8. McDonald S, Excell L, Livingston B (eds) 2008. Australia and New Zealand Dialysis and Transplant Registry: Adelaide. pp. 1-97. Appendix II, in ANZDATA Registry Report 2008
9. Yamagata K et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008; 12: 1-8
10. Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 2002; 13: S37-S40
11. Adler A et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232
12. Retnakaran R et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839
13. Parving H et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063
14. Ninomiya T et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821
15. Dunstan D et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834
16. White S et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008; 188: 204-208
17. Whaley-Connell A et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53(Suppl 4): S11-S21
18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008; 4: 2-3
19. Holman R et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabetes Med 2008; 25(Suppl 2): 25-29
21. Gaede P et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
22. Patel A et al. Effects of a fixed combination of perindopril and in-dapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
23. Group AC et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
24. Zoungas S et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvas-cular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 3 August 2009; [Epub ahead of print]
25. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
26. Parving H et al. The effectof irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878 (Pubitemid 34940826)
27. Lewis E et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-860
28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009; 18: 107-111